Clintabs: Product Information

CLINTABS- clindamycin hydrochloride tablet
Virbac AH, Inc.

DESCRIPTION

Clintabs Tablets contain clindamycin hydrochloride which is the hydrated salt of clindamycin. Clindamycin is a semisyntheic antibiotic produced by a 7(S)-chlorosubstitution of the 7(R)-hydroxyl group of a naturally produced antibiotic produced by Streptomyces lincolnensis var. lincolnensis.

Clintabs Tablets (For Use in Dogs Only)

25 mg Tablet, each white bisected tablet is marked “C” above the bisect and “25” below the bisect and contains clindamycin hydrochloride equivalent to 25 mg of clindamycin.

75 mg Tablet, each white bisected tablet is marked “C” above the bisect and “75” below the bisect and contains clindamycin hydrochloride equivalent to 75 mg of clindamycin.

150 mg Tablet, each white tablet is marked “C 150” on one side and contains clindamycin hydrochloride equivalent to 150 mg of clindamycin.

ACTIONS

Site and Mode of Action

Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 50S sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from cell wall inhibitors in that it causes irreversible modification of the protein-synthesizing subcellular elements at the ribosomal level.

MICROBIOLOGY

Clindamycin is a lincosaminide antimicrobial agent with activity against a wide variety of aerobic and anaerobic bacterial pathogens. Clindamycin is a bacteriostatic compound that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The minimum inhibitory concentrations (MICs) of Gram-positive and obligate anaerobic pathogens isolated from dogs in the United States are presented in Table 1. Bacteria were isolated in 1998-1999. All MICs were performed in accordance with the National Committee for Clinical Laboratory Standards (NCCLS).

Table 1. Clindamycin MIC Values (µg/mL) from Diagnostic Laboratory Survey Data Evaluating Canine Pathogens in the U.S. during 1998-99*
Organism Number of Isolates MIC50 MIC85 MIC90 Range
*
The correlation between the in vitro susceptibility data and clinical response has not been determined.
Soft Tissue/Wound: includes samples labeled wound, abscess, aspirate, exudates, draining tract, lesion, and mass
Osteomyelitis/Bone: includes samples labeled bone, fracture, joint, tendon
§
No range, all isolates yielded the same value
Dermal/Skin: includes samples labeled skin, skin swab, biopsy, incision, lip
Soft Tissue/Wound
Staphylococcus aureus 17 0.5 0.5 ≥4.0 0.25-≥4.0
Staphylococcus intermedius 28 0.25 0.5 ≥4.0 0.125-≥4.0
Staphylococcus spp. 18 0.5 0.5 ≥4.0 .025-≥4.0
Beta-hemolytic streptococci 46 0.5 0.5 ≥4.0 0.25-≥4.0
Streptococcus spp. 11 0.5 ≥4.0 ≥4.0 0.25-≥4.0
Osteomyelitis/Bone
Staphylococcus aureus 20 0.5 0.5 0.5 0.5§
Staphylococcus intermedius 15 0.5 ≥4.0 ≥4.0 0.25-≥4.0
Staphylococcus spp. 18 0.5 ≥4.0 ≥4.0 0.25-≥4.0
Beta-hemolytic streptococci 21 0.5 2.0 2.0 0.25-≥4.0
Streptococcus spp. 21 ≥4.0 ≥4.0 ≥4.0 0.25-≥4.0
Dermal/Skin
Staphylococcus aureus 25 0.5 ≥4.0 ≥4.0 0.25-≥4.0
Staphylococcus intermedius 48 0.5 ≥4.0 ≥4.0 0.125-≥4.0
Staphylococcus spp. 32 0.5 ≥4.0 ≥4.0 0.25-≥4.0
Beta-hemolytic streptococci 17 0.5 0.5 0.5 0.25-0.5

PHARMACOLOGY

Absorption

Clindamycin hydrochloride is rapidly absorbed from the canine gastrointestinal tract.

Dog Serum Levels

Serum levels at or above 0.5 µg/mL can be maintained by oral dosing at a rate of 2.5 mg/lb of clindamycin hydrochloride every 12 hours. This same study revealed that average peak serum concentrations of clindamycin occur 1 hour and 15 minutes after oral dosing. The elimination half-life for clindamycin in dog serum was approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses in healthy dogs.

image description
(click image for full-size original)

METABOLISM AND EXCRETION

Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and bioinactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected in serum after clindamycin hydrochloride administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites, especially N-dimethyl clindamycin and clindamycin sulfoxide.

Page 1 of 2 1 2

VetLabel.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VetLabel.com. Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

Our database mirrors the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. VetLabel.com provides the full animal health subset of the FDA's repository. Veterinary information provided here is not intended as a substitute for direct consultation with a qualified veterinary professional.

Terms of Use | Copyright © 2021. All Rights Reserved.